Evotec refines its drug discovery strategy, shares tracked on Xetra consensus views
22.06.2026 - 20:23:57 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-22, 20:21.
Evotec (DE0005664809) remains one of the better-known German biotech names on Xetra, with the stock trading in the mid-single-digit euro range in recent sessions. Analyst estimates compiled on financial portals cluster around a moderate upside scenario based on the company’s fee-for-service and milestone-driven partnership model.
What consensus data indicate
Several analyst aggregation services still track Evotec with a mix of Buy, Hold and occasional Sell recommendations, reflecting the typical risk profile of a small to mid-cap biotechnology platform company. MarketScreener’s consolidated view for Evotec points to a consensus rating in the Buy to Hold corridor, with an average 12-month price target that implies upside from the latest Xetra price, although the exact distribution of ratings and targets can shift as new notes are published over time MarketScreener consensus overview for Evotec.
German-language platforms such as finanzen.net and finanzen.ch mirror this picture, listing multiple research houses that follow the stock and publish fair-value assumptions, often in a target-price band spanning roughly the low to high single digits in euros for the Xetra listing finanzen.net target-price compilation for Evotec. The number of active analyst opinions tends to remain in the low double digits, which is common for a specialized biotech with a primary listing in Frankfurt.
How Evotec earns its revenue
Operationally, Evotec positions itself as a drug discovery and development platform that works mainly in partnerships with large pharmaceutical and biotechnology companies rather than relying solely on fully owned late-stage assets Evotec corporate description of its business model. The group generates revenue from research fees, milestones and potential royalties across therapeutic areas such as neurology, oncology and metabolic diseases, using proprietary technology platforms to run high-throughput screening, medicinal chemistry and preclinical development programs for its partners.
This partnering-heavy approach spreads scientific and financial risk across multiple collaborations, while also creating a pipeline of potential long-term royalty streams if partnered candidates reach approval. At the same time, it ties Evotec’s near-term performance closely to the pace and scope of partner R&D spending and to the timing of individual milestones, which can make quarterly figures comparatively volatile compared with more mature pharmaceutical peers.
All news and analysis on the Evotec shares
Further corporate disclosures, research notes and price data for Evotec are collected on dedicated topic pages and in the company’s own investor relations section.
The product engine behind the stock
In practical terms, Evotec’s business model revolves around its integrated discovery platforms, for example in small-molecule drug discovery where it uses high-throughput screening, structural biology and medicinal chemistry to identify and optimize new compounds for partners. Alongside such fee-based discovery programs, Evotec also advances selected proprietary or co-owned assets into early clinical stages, particularly in areas like neurological and metabolic diseases, with the aim of sharing future upside through out-licensing or co-development structures.
Where the shares trade today
The Evotec shares (DE0005664809) most actively trade on Xetra in euros; recent data on Deutsche Börse and major financial portals place the price in the mid-single-digit range, with a market capitalization in the low to mid one-digit billion-euro band based on those levels Deutsche Börse overview for Evotec.
Key data on the Evotec shares
- Company: Evotec SE
- ISIN: DE0005664809
- WKN: 566480
- Ticker: EVT
- Trading venue: Xetra
- Price (as of latest available Xetra data): mid-single-digit euro range
- Market cap: low to mid one-digit billion-euro range (based on recent Xetra prices)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: TecDAX
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or a solicitation of any kind. Figures and assessments are based on sources deemed reliable but cannot be guaranteed.
